- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04224974
Prova di coinvolgimento incentrata sull'emozione e sui sintomi per individui con leucemia acuta (EASE)
Emozione e coinvolgimento incentrato sui sintomi (EASE): uno studio controllato randomizzato multi-sito di un intervento per gli individui con leucemia acuta
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Harriet Richardson
- Numero di telefono: 613-533-6430
- Email: hrichardson@ctg.queensu.ca
Backup dei contatti dello studio
- Nome: Lois Shepherd
- Numero di telefono: 613-533-6430
- Email: lshepherd@ctg.queensu.ca
Luoghi di studio
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Reclutamento
- Regional Health Authority B, Zone 2
-
Contatto:
- Alfonso Rivera Duarte
- Numero di telefono: 506 648-7109
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Reclutamento
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contatto:
- Alejandro Garcia-Horton
-
Kingston, Ontario, Canada, K7L 2V7
- Reclutamento
- Kingston Health Sciences Centre
-
Contatto:
- Annette Hay
- Numero di telefono: 77094 613 533-6430
-
Ottawa, Ontario, Canada, K1H 8L6
- Reclutamento
- Ottawa Hospital Research Institute
-
Contatto:
- Pierre Villeneuve
- Numero di telefono: 613
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- University Health Network
-
Contatto:
- Gary Rodin
- Numero di telefono: 416 946-4504
-
Toronto, Ontario, Canada, M4N 3M5
- Reclutamento
- Odette Cancer Centre
-
Contatto:
- Lee Mozessohn
- Numero di telefono: 5847 416 480-5000
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Altro: Cure abituali
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
Sperimentale: Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
Lasso di tempo: 4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Valutare l'effetto dell'intervento EASE rispetto alle cure abituali per ridurre i sintomi di stress traumatico utilizzando il SASRQ
Lasso di tempo: 8 settimane, 12 settimane e 26 settimane
|
8 settimane, 12 settimane e 26 settimane
|
|
|
Valutare l'effetto dell'intervento EASE sulle cure abituali per ridurre la gravità dei sintomi fisici utilizzando il MSAS
Lasso di tempo: 8 settimane, 12 settimane e 26 settimane
|
8 settimane, 12 settimane e 26 settimane
|
|
|
Valutare l'effetto dell'intervento EASE rispetto alle cure abituali sul numero di partecipanti che soddisfano i criteri coerenti con una diagnosi di ASD e soglia ASD basata sui criteri del DSM-5 utilizzando il SASRQ
Lasso di tempo: 4, 8, 12 e 26 settimane
|
4, 8, 12 e 26 settimane
|
|
|
Valutare l'effetto dell'intervento EASE rispetto alle cure abituali sul numero di sintomi fisici del cancro e sul disagio associato ai sintomi misurato dal (MSAS)
Lasso di tempo: 4, 8, 12 e 26 settimane
|
4, 8, 12 e 26 settimane
|
|
|
Valutare l'effetto dell'intervento EASE rispetto all'assistenza abituale sulla soddisfazione del paziente con l'assistenza utilizzando il FAMCAR-P16 a 16 item
Lasso di tempo: 4, 8, 12 e 26 settimane
|
4, 8, 12 e 26 settimane
|
|
|
10) L'EQ-5D-5L sarà utilizzato per misurare lo stato di salute generico in modo che possa essere utilizzato per calcolare gli anni di vita aggiustati per la qualità (QALY) in una valutazione economica che confronti il beneficio e il costo dell'intervento EASE
Lasso di tempo: 4, 8, 12, 26 e 52 settimane
|
4, 8, 12, 26 e 52 settimane
|
|
|
Confrontare la sopravvivenza libera da progressione tra i bracci di trattamento
Lasso di tempo: 1 anno
|
1 anno
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
Lasso di tempo: 4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
Lasso di tempo: 4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
Lasso di tempo: 4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
Lasso di tempo: 4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
Lasso di tempo: Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Gary Rodin, Princess Margaret Hospital, Canada
- Cattedra di studio: Camilla Zimmerman, Princess Margaret Hospital, Canada
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- SC26
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .